Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
RESEARCH TRIANGLE PARK, N.C., March 29, 2017 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company’s clinical programs at the 16th Annual Needham Healthcare Conference in New York on Tuesday, April 4, 2017 at 8:40 AM Eastern Time.
Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst currently has several ongoing development programs: BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema, and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is a potential treatment for filoviruses. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Japan, Taiwan and Korea. Post-marketing commitment development activities are ongoing, as well as activities to support regulatory approvals in other territories. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
CONTACT: Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910
